Cargando…

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Diabetes is a major cause of visual impairment among working-age adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity <5/200). The standard treatment in proliferative diabetic retinopathy (PDR) is panretinal photocoagulation (PR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yue, Singh, Rishi P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113746/ https://www.ncbi.nlm.nih.gov/pubmed/30181760 http://dx.doi.org/10.7573/dic.212532

Ejemplares similares

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy
por: Raman, Rajiv, et al.
Publicado: (2022)

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
por: Bahr, Tyler A., et al.
Publicado: (2023)

The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment
por: Tremolada, Gemma, et al.
Publicado: (2012)

Review of Studies Comparing Panretinal Photocoagulation and Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Proliferative Diabetic Retinopathy
por: Gunasekaran, Thiruvarasu, et al.
Publicado: (2022)

Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan
por: Hsieh, Ming-Chieh, et al.
Publicado: (2022)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis
por: Wang, Dong-yue, et al.
Publicado: (2020)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
por: Takayama, Kei, et al.
Publicado: (2021)

Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries
por: Dogra, Mangat Ram, et al.
Publicado: (2023)

Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy
por: Petrovič, Mojca Globočnik, et al.
Publicado: (2008)

Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
por: Chung, Eun Jee, et al.
Publicado: (2011)

Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
por: Wu, Lihteh, et al.
Publicado: (2019)

Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy
por: Chen, Hui-Jin, et al.
Publicado: (2019)

Comparative Analysis of the Effects of the Anti-VEGF Drug and Glucocorticoid by Injection before the End of Vitrectomy for Proliferative Diabetic Retinopathy
por: Zhao, Haijin, et al.
Publicado: (2021)

Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF(165)b Isoform in the Vitreous of Patients with Retinopathy of Prematurity
por: Zhao, Min, et al.
Publicado: (2015)

Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity
por: Sindal, Manavi D, et al.
Publicado: (2021)

Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy
por: Parravano, Mariacristina, et al.
Publicado: (2022)

Vitreous and Serum Concentrations of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Proliferative Diabetic Retinopathy
por: Muhiddin, Habibah Setyawati, et al.
Publicado: (2020)

Anti-Vascular Endothelial Growth Factor Therapy as an Alternative or Adjunct to Pan-Retinal Photocoagulation in Treating Proliferative Diabetic Retinopathy: Meta-Analysis of Randomized Trials
por: Gao, Shuang, et al.
Publicado: (2020)

Relationship between Vitreous Levels of Matrix Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic Retinopathy
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2013)

Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy
por: Gao, Xinxiao, et al.
Publicado: (2015)

Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy
por: Russo, Andrea, et al.
Publicado: (2019)

Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy
por: Nguyen, Quan Dong, et al.
Publicado: (2023)

Combined Use of Anti-VEGF Drugs Before and During Pars Plana Vitrectomy for Severe Proliferative Diabetic Retinopathy
por: Sun, Xincheng, et al.
Publicado: (2023)

Clinical efficacy of anti-vascular endothelial growth factor versus panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis
por: Lin, Yuxian, et al.
Publicado: (2021)

Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2
por: Alkin, Zeynep, et al.
Publicado: (2016)

Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review
por: Tan, Qing-Qing, et al.
Publicado: (2019)

The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
por: Kuiper, Esther J., et al.
Publicado: (2008)

Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)
por: Li, Zijing, et al.
Publicado: (2018)

Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy
por: Baharivand, Nader, et al.
Publicado: (2012)

Growth Factors in Proliferative Diabetic Retinopathy
por: Khan, Zia Ali, et al.
Publicado: (2003)

Diabetic retinopathy and vascular endothelial growth factor
por: Khazaei, Majid
Publicado: (2013)

Relationships among Retinal Nonperfusion, Neovascularization, and Vascular Endothelial Growth Factor Levels in Quiescent Proliferative Diabetic Retinopathy
por: Ra, Ho, et al.
Publicado: (2020)

Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy
por: Shye, Michael, et al.
Publicado: (2020)

Effect of pan-retinal laser photocoagulation on intravitreal vascular endothelial growth factor concentration in proliferative diabetic retinopathy
por: Nišić, Faruk, et al.
Publicado: (2022)

Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α
por: Han, Xiao-Xia, et al.
Publicado: (2012)

Retracted: Comparative Analysis of the Effects of the Anti-VEGF Drug and Glucocorticoid by Injection before the End of Vitrectomy for Proliferative Diabetic Retinopathy
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
por: Chatziralli, Irini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ea1dqkvrodkmed9dicurabj1re